Ablation of the deubiquitinase USP15 ameliorates nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

참고문헌 (58)

1. Byrne, C. D., "NAFLD : a multisystem disease", J. Hepatol, 62, pp.S47~S64 (2015)
2. Danford, C. J., "NAFLD : a multisystem disease that requires a multidisciplinary approach", Frontline Gastroenterol, 10, pp.328~329 (2019)
3. Young, S., "Prevalence and profile of nonalcoholic fatty liver disease in lean adults : systematic review and meta-analysis", Hepatol. Commun, 4, pp.953~972 (2020)
4. Michelotti, G. A., "NAFLD, NASH and liver cancer", Nat. Rev. Gastroenterol. Hepatol, 10, pp.656~665 (2013)
5. Eslam, M., "Genetics and epigenetics of NAFLD and NASH : Clinical impact", J. Hepatol, 68, pp.268~279 (2018)
6. Rinella, M. E, "Management of NAFLD: a stage-based approach", Nat. Rev. Gastroenterol. Hepatol, 13, pp.196~205 (2016)
7. Younes, R., "Should we undertake surveillance for HCC in patients with NAFLD", J. Hepatol, 68, pp.326~334 (2018)
8. Kenneally, S., "Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease : a systematic review", BMJ Open Gastroenterol, 4, pp.e000139~ (2017)
9. Chen, Z., "Ubiquitin-specific protease 1 acts as an oncogene and promotes lenvatinib efficacy in hepatocellular carcinoma by stabilizing c-kit", Ann. Hepatol, 27, pp.100669~ (2022)
10. Du, Z., "Ubiquitin specific peptidase 1 promotes hepatic fibrosis through positive regulation of CXCL1 by deubiquitinating SNAIL", Dig. Liver Dis, 54, pp.91~102 (2022)
11. Kamoshita, K., "Insulin suppresses ubiquitination via the deubiquitinating enzyme USP14, independent of proteasome activity in H4IIEC3 hepatocytes", J. Pharmacol. Exp. Ther (2022)[DOI]
12. Popovic, D., "Ubiquitination in disease pathogenesis and treatment", Nat. Med, 20, pp.1242~1253 (2014)
13. Clague, M. J., "Breaking the chains : deubiquitylating enzyme specificity begets function", Nat. Rev. Mol. Cell Biol, 20, pp.338~352 (2019)
14. Ji, Y. X., "The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis", Nat. Med, 24, pp.213~223 (2018)
15. Luo, P., "Ubiquitin-specific peptidase 10(USP10)inhibits hepatic steatosis, insulin resistance, and inflammation through Sirt6", Hepatology, 68, pp.1786~1803 (2018)
16. Ghosh, M., "Ubiquitin ligase COP1 controls hepatic fat metabolism by targeting ATGL for degradation", Diabetes, 65, pp.3561~3572 (2016)
17. Zhang, P., "The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis", Nat. Med, 24, pp.84~94 (2018)
18. Eichhorn, P. J., "USP15 stabilizes the TGF-beta receptor I and promotes oncogenesis through the activation of the TGF-beta signal in glioblastoma", Cancer Res (2012)[DOI]
19. Zhou, Q. Q., "USP15 potentiates NF-kappa B activation by differentially stabilizing TAB2 and TAB3", FEBS J, 287, pp.3165~3183 (2020)
20. Villeneuve, N. F., "USP15 negatively regulates Nr12 through deubiquitination of Keap1", Mol. Cell, 51, pp.68~79 (2013)
21. Zou, Q., "USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses", Nat. Immunol, 15, pp.562~570 (2014)
22. Kusakabe, S., "USP15 participates in hepatitis C virus propagation through regulation of viral RNA translation and lipid droplet formation", J. Virol (2019)[DOI]
23. Cheng, D., "MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity", Cell Metab, 34, pp.1732~1748 (2022)
24. Knorr, J., "Interleukin-18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis", Hepatology (2022)[DOI]
25. 김남준, "A PDE1 inhibitor reduces adipogenesis in mice via regulation of lipolysis and adipogenic cell signaling", Experimental and Molecular Medicine, 51, pp.1~15 (2019), 생화학분자생물학회[DOI]
26. 백정환, "Kahweol inhibits lipid accumulation and induces Glucose-uptake through activation of AMP-activated protein kinase (AMPK)", BMB Reports, 50(11), pp.566~571 (2017), 생화학분자생물학회
27. Min-Seon Hwang, "Tschimganidine reduces lipid accumulation through AMPK activation and alleviates high-fat diet-induced metabolic diseases", BMB Reports, 56(4), pp.246~251 (2023), 생화학분자생물학회
28. Baek, J. H., "Galectin-1 accelerates high-fat diet-induced obesity by activation of peroxisome proliferator-activated receptor gamma (PPARγ) in mice", Cell Death Dis, 12, pp.66~ (2021)
29. Jae-Ho Lee, "Isocitrate dehydrogenase 2 protects mice from high-fat diet-induced metabolic stress by limiting oxidative damage to the mitochondria from brown adipose tissue", Experimental and Molecular Medicine, 52, pp.1~15 (2020), 생화학분자생물학회[DOI]
30. Kim, S. J., "Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression", Gastroenterology, 138, pp.1035~1045 (2010)
31. Cho, Y., "Post-translational modification of OCT4 in breast cancer tumorigenesis", Cell Death Differ (2018)[DOI]
32. Nguyen, T. V., "Glutamine triggers acetylation-dependent degradation of glutamine synthetase via the thalidomide receptor cereblon", Mol. Cell, 61, pp.809~820 (2016)
33. Nguyen, T. V., "p97", VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates, 2017, pp.114, 3565~3571
34. Nguyen, T. V., "USP15 antagonizes CRL4(CRBN)-mediated ubiquitylation of glutamine synthetase and neosubstrates", Proc. Natl Acad. Sci. USA (2021)[DOI]
35. Baek, J. H., "Galectin-3 activates PPARgamma and supports white adipose tissue formation and high-fat diet-induced obesity", Endocrinology, 156, pp.147~156 (2015)
36. Charni-Natan, M., "Protocol for primary mouse hepatocyte isolation", STAR Protoc, 1, pp.100086~ (2020)
37. Kleiner, D. E., "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", Hepatology, 41, pp.1313~1321 (2005)
38. Kim, S. J., "Activation of nuclear PTEN by inhibition of Notch signaling induces G2", M cell cycle arrest in gastric cancer, 2016, pp.35, 251~260
39. Oligschlaeger, Y., "NAFLD preclinical models: more than a handful, less of a concern?", Biomedicines (2020)[DOI]
40. Chen, J. L., "Kruppel-like factor 2 promotes liver steatosis through upregulation of CD36", J. Lipid Res, 55, pp.32~40 (2014)
41. Kim, J. H., "Histone H3K9 demethylase JMJD2B induces hepatic steatosis through upregulation of PPARgamma2", Sci. Rep, 8, pp.13734~ (2018)
42. Lee, Y. J., "Nuclear receptor PPARgamma-regulated monoacylglycerol O-acyltransferase 1(MGAT1)expression is responsible for the lipid accumulation in diet-induced hepatic steatosis", Proc. Natl Acad. Sci. USA, 109, pp.13656~13661 (2012)
43. Wang, X., "Hepatocyte TAZ", WWTR1 promotes inflammation and fibrosis in nonalcoholic steatohepatitis, 2016, pp.24, 848~862
44. Hsieh, Y. C., "(Pro)renin receptor knockdown attenuates liver fibrosis through inactivation ERK", TGF-beta 1, Cell Mol. Gastroenter, pp.2021, 12[DOI]
45. Ji, J., "Apigenin alleviates liver fibrosis by inhibiting hepatic stellate cell activation and autophagy via TGF-beta 1", Smad3 and p38, PPAR Res, pp.2021, 2021[DOI]
46. Zhong, X. L., "SIRT6 protects against liver fibrosis by deacetylation and suppression of SMAD3 in hepatic stellate cells", Cell Mol. Gastroenter, 10, pp.341~364 (2020)
47. Mirzayans, R., "Do TUNEL and other apoptosis assays detect cell death in preclinical studies?", Int. J. Mol. Sci, 21, pp.9090~ (2020)
48. An, S., "USP18 protects against hepatic steatosis and insulin resistance through its deubiquitinating activity", Hepatology, 66, pp.1866~1884 (2017)
49. Yang, L., "Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice", Hepatology, 59, pp.483~495 (2014)
50. Sunami, Y., "Hepatic activation of IKK", NFkappaB signaling induces liver fibrosis via macrophage-mediated chronic inflammation, 2012, pp.56, 1117~1128
51. Furuhashi, M., "Fatty acid-binding protein 4(FABP4) : pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular diseases", Clin. Med. Insights Cardiol, 8, pp.23~33 (2014)
52. Mukai, T., "Silencing of FABP1ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease", FEBS Open Bio, 7, pp.1009~1016 (2017)
53. Uysal, K. T., "Improved glucose and lipid metabolism in genetically obese mice lacking aP2", Endocrinology, 141, pp.3388~3396 (2000)
54. Sohn, J. H., "Perilipin 1(Plin1)deficiency promotes inflammatory responses in lean adipose tissue through lipid dysregulation", J. Biol. Chem, 293, pp.13974~13988 (2018)
55. Orlicky, D. J., "Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions", J. Physiol, 597, pp.1565~1584 (2019)
56. Najt, C. P., "Liver-specific loss of Perilipin 2 alleviates diet-induced hepatic steatosis, inflammation, and fibrosis", Am. J. Physiol. Gastrointest. Liver Physiol, 310, pp.G726~G738 (2016)
57. Joshi-Barve, S., "Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes", Hepatology, 46, pp.823~830 (2007)
58. Vergnes, L., "Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression", J. Biol. Chem, 278, pp.42774~42784 (2003)

관련 논문AI추천